Pharmacogenetics in Cancer Treatment

Annual Review of Medicine

Volumn 54, Issue , 2003, Pages 437-452

  Nagasubramanian, R ^a   Innocenti, F ^a   Ratain, M J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Chemotherapy; Drug metabolism; Drug response; Polymorphisms; Toxicity

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); 6 MERCAPTOPURINE DERIVATIVE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACYLTRANSFERASE; ANTINEOPLASTIC AGENT; AZATHIOPRINE; CYTOCHROME P450 2D6; DIHYDROPYRIMIDINE DEHYDROGENASE; DOCETAXEL; FC RECEPTOR; FLUOROURACIL; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE TRANSFERASE; IMMUNOGLOBULIN G1; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; METHYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN; OXALIPLATIN; RALTITREXED; RITUXIMAB; SULFOTRANSFERASE; THIOPURINE S METHYLTRANSFERASE; THYMIDYLATE SYNTHASE; TIOGUANINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; AUTOIMMUNE DISEASE; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM CANCER; DNA DAMAGE; DNA REPAIR; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG TARGETING; DRUG TRANSFORMATION; DRUG TRANSPORT; DRUG UPTAKE; ENZYME ACTIVITY; FOLATE METABOLISM; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; GILBERT DISEASE; HEAD AND NECK CANCER; HIGH RISK PATIENT; HUMAN; HYPERBILIRUBINEMIA; MORTALITY; MOUTH MUCOSA; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVARY CANCER; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROMOTER REGION; PSEUDOGENE; PURINE METABOLISM; PYRIMIDINE METABOLISM; REVIEW; SIDE EFFECT; SOLID TUMOR; TATA BOX; TUMOR CELL LINE; VARIABLE NUMBER OF TANDEM REPEAT; WERNER SYNDROME; WRN GENE; X RAY CROSS COMPLEMENTING GROUP 1 GENE; XERODERMA PIGMENTOSUM; XPD GENE; XRCC1 GENE; BIOTRANSFORMATION; DRUG DETOXIFICATION; GENETICS; NEOPLASM; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; HUMANS; METABOLIC DETOXICATION, DRUG; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 0038654356     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.54.101601.152352     Document Type: Review

References (76)

1. Nebert DW. 1999. Pharmacogenetics and pharmacogenomics: Why is this relevant to the clinical geneticist? Clin. Genet. 56:247-58
2. http://www.genome.gov/glossary
3. Leeder SJ. 2001. Pharmacogenetics and pharmacogenomics. Pediatr. Clin. North Am. 48(3):765-81
4. Roy CJ, Novikoff PM, Roy CN, et al. 1985. Distribution of UDP-glucuronosyl transferases in rat tissue. Proc. Natl. Acad. Sci. USA 82(9):2990-94
5. Hanioka N, Ozawa S, Jinno H, et al. 2001. Human liver UDP-glucuronyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica 31(10):687-99
6. Mackenzie PI, Owens IS, Burchell B, et al. 1997. The UDP- glucuronyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7:255-69
7. Bosma PJ, Seppen J, Goldhoorn B, et al. 1994. Bilirubin UDP-glucuronyl transferase 1 is the only relevant bilirubin glucuronidating isoform in man. J. Biol. Chem. 269:17960-64
8. Kadakol A, Ghosh SS, Sappal BS, et al. 2000. Genetic lesions of bilirubin uridine-diphosphoglucuronate-glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Mutat. Update 16:297-306
9. Bosma PJ, Roy CJ, Bakker C, et al. 1995. A sequence abnormality in the promoter region results in reduced expression of bilirubin-UDP- glucuronosyltransferase-1 in Gilbert's syndrome. N. Engl. J. Med. 333:1171-75
10. Monaghan G, Ryan M, Seddon R, et al. 1996. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347:578-81
11. Monaghan G, Foster B, Jurima-Romet M, et al. 1997. UGT1*1 genotyping in a Canadian Inuit population. Pharmacogenetics 7:153-56
12. Beutler E, Gelbart T, Demina A. 1998. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl. Acad. Sci. USA 95:8170-74
13. Sato H, Adachi Y, Koiwai O. 1996. The genetic basis of Gilbert's syndrome. Lancet 347:557-58
14. Humerickhouse R, Lohrbach K, Li L, et al. 2000. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res. 60:1189-92
15. Gupta E, Lestingi TM, Mick R, et al. 1994. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 54:3723-25
16. Iyer L, Hall D, Das S, et al. 1999. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin. Pharmacol. Ther. 65(5):576-82
17. Wasserman E, Myara A, Lokiec F, et al. 1997. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann. Oncol. 9:1049-51
18. Ando Y, Saka H, Ando M, et al. 2000. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60:6921-26
19. Iyer L, Das S, Janish L, et al. 2002. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenom. J. 2:43-47
20. Wrighton SA, Brian WR, Sari MA, et al. 1990. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5. Mol. Pharmacol. 38:207-13
21. Yvonne SL, Amy LS, Dowling SD, et al. 2002. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol. 62:162-72
22. Dai D, Zeldin DC, Blaisdell JA, et al. 2001. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11(7):597-607
23. Weinshilboum RM, Sladek S. 1980. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32:651-52
24. Szumlanski C, Otterness D, Her C, et al. 1996. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell. Biol. 15:17-30
25. Tai HL, Krynetski EY, Schuetz EG, et al. 1997. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*20): mechanisms for the genetic polymorphism of TPMT activity. Proc. Natl. Acad. Sci. USA 94:6444-49
26. Yan L, Zhang S, Eiff B, et al. 2000. Thiopurine methyltransferase (TPMT) promoter variable number tandem repeat (VNTR) polymorphism: genotype-phenotype correlation analysis for 1211 patients. Clin. Pharmacol. Ther. 68:210-19
27. Evans WE, Horner M, Chu YQ, et al. 1991. Altered mercaptopurine metabolism, toxic effects and dosage requirement in a thiopurine methyltransferase deficient child with acute lymphoblastic leukemia. J. Pediatr. 119:985-89
28. Schutz E, Gummert J, Mohr F, et al. 1993. Azathiopurine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipients. Lancet 341:436
29. Lennard L, Welch JC, Lilleyman JS, et al. 1997. Thiopurine drugs in the treatment of childhood leukemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. Br. J. Clin. Pharmacol. 44:455-61
30. Evans WE, Hon YY, Bomgaars L, et al. 2001. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathiopurine. J. Clin. Oncol. 19(8):2293-301
31. Relling MV, Hancock ML, Rivera GK, et al. 1999. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine methyltransferase gene locus. J. Natl. Cancer. Inst. 91(23):2001-8
32. Relling MV, Hancock ML, Boyett JM, et al. 1999. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93(9): 2817-23
33. Lennard L, Lilleyman JS, Van Loon J, et al. 1990. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia. Lancet 336:225-29
34. 33a. McLeod HL, Evans WE. 2001. Pharmacogenetics: unlocking the human genome for better drug therapy. Annu. Rev. Pharmacol. Toxicol. 41:101-21
35. Wasternack C. 1980. Degradation of pyrimidines and pyrimidine analogs - pathways and mutual influences. Pharmacol. Ther. 8:629-52
36. Heggie GD, Sommadossi J-P, Cross DS, et al. 1987. Clinical pharmacokinetics of 5-fluorouracil and its metabolism in plasma, urine and bile. Cancer Res. 47: 2203-306
37. Baker SD, Diasio RB, O'Reilly S, et al. 2000. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. J.Clin.Oncol. 4:915-26
38. Tuchman M, Stoeckeler JS, Kiang DT, et al. 1985. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N. Engl. J. Med. 313 (4):245-49
39. Harris BE, Carpenter JT, Diaso RB. 1991. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: a potentially more common pharmacogenetic syndrome. Cancer 69:499-501
40. Wei X, McLeod HD, McMurrough J, et al. 1996. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest. 98:610-15
41. Johnson MR, Diasio RB. 2001. Importance of dihydrpyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv. Enzyme. Regul. 41: 151-57
42. Milano G, Etienne MC. 1994. Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil. Anticancer Res. 14:2295-97
43. Milano G, Etienne MC, Pierrefite V, et al. 1999. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br. J. Cancer 79(3-4):627-30
44. van Kuilenberg AB, Haasjes J, Richel DJ, et al. 2000. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-asociated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 6:4705-12
45. Wei X, Elizondo G, Sapone A, et al. 1996. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 51:391-400
46. van Kuilenberg AB, Muller EW, Haasjes J, et al. 2001. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil. Frequency of the common IVS14 + IG > A mutation causing DPD deficiency. Clin. Cancer Res. 7(5):1149-53
47. Raida M, Schwabe W, Hausler P, et al. 2001. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared to controls. Clin. Cancer Res. 7:2832-39
48. Collie-Duguid ES, Etienne MC, Milano G, et al. 2000. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 10(30):217-23
49. Deleted in proof
50. Rutsum YM, Harstrick A, Cao S, et al. 1997. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J. Clin. Oncol. 15:389-400
51. Nishimura R, Nagao K, Miyayama H, et al. 1999. Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer. Anticancer Res. 19:5621-26
52. Leichman CG, Lenz HJ, Leichman L, et al. 1997. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol. 15:3223-29
53. van Triest B, Pinedo HM, van Hensbergen Y, et al. 1999. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin. Cancer Res. 5:643-54
54. Kawakami K, Omura K, Kanehira E, et al. 1999. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res. 19(4B):3249-52
55. Marsh S, Collie-Duguid ES, Li T, et al. 1999. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 58:310-12
56. Marsh S, McKay JA, Cassidy J, et al. 2001. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int. J. Clin. Oncol. 19:383-86
57. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. 2001. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenom. J. 1:65-70
58. Iacopetta B, Grieu F, Joseph D, et al. 2001. A polymorphism in the enhancer region of the thymidylate synthase gene influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br. J. Cancer 85:827-30
59. Krajinovic M, Costea I, Chiasson S. 2002. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukemia. Lancet 359:1033-34
60. Reff ME, Carner K, Chambers KS, et al. 1994. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-45
61. Shan D, Ledbetter JA, Press OW. 1998. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91:1644-52
62. Cartron G, Dacheux L, Salles G, et al. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99:754-58
63. Koene HR, Kleijer M, Algra J, et al. 1997. FcγRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcγRIIIa, independently of the FcγRIIIa-48L/R/H phenotype. Blood 90:1109-14
64. Frosst P, Blom HJ, Milos R, et al. 1995. A candidate genetic risk factor for vascular disease; a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10:111-13
65. Schneider JA, Rees DC, Liu YT, et al. 1998. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am. J. Hum. Genet. 62:1258-60
66. Ulrich CM, Yasui Y, Storb R, et al. 2001. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98:231-34
67. Toffoli G, Veronesi A, Boiocchi M, et al. 2000. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate and fluorouracil (CMF). Ann. Oncol. 11:373-75
68. Stevenson JP, Redlinger M, Kluijtmans LAJ, et al. 2001. Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer. J. Clin. Oncol. 19(20):4081-87
69. Reed E. 1998. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat. Rev. 24(5):331-44
70. Park DJ, Stoehlmacher J, Zhang W, et al. 2001. A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 61(24):8654-58
71. Thompson LH, West MG. 2002. XRCC1 keeps DNA from getting stranded. Mutat. Res. 459:1-18
72. Stoehlmacher J, Ghaderi V, Iobal S, et al. 2001. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res. 21(4B):3075-79
73. Poot M, Gollahon KA, Rabinovitch PS. 1999. Werner syndrome lymphoblastoid cells are sensitive to camptothecin-induced apoptosis in S-phase. Hum. Genet. 104(1):10-14
74. Castro E, Ogburn CE, Hunt KE, et al. 1999. Polymorphisms at the Werner locus. I. Newly identified polymorphisms, ethnic variability of 1367Cys/Arg, and its stability in a population of Finnish centenarians. Am. J. Med. Genet. 82(5):399-403
75. Conrad S, Kauffmann HM, Ito K, et al. 2002. A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 12(4):321-30
76. Ameyaw MM, Regateiro F, Li T, et al. 2001. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11(3):217-21